Attached files

file filename
EX-31.2 - EX-31.2 - ALNYLAM PHARMACEUTICALS, INC.d849416dex312.htm
EX-10.5 - EX-10.5 - ALNYLAM PHARMACEUTICALS, INC.d849416dex105.htm
EX-31.1 - EX-31.1 - ALNYLAM PHARMACEUTICALS, INC.d849416dex311.htm
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q/A

Amendment No. 1

 

 

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number 001-36407

 

 

ALNYLAM PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   77-0602661

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

300 Third Street, Cambridge, MA   02142
(Address of Principal Executive Offices)   (Zip Code)

(617) 551-8200

(Registrant’s Telephone Number, Including Area Code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   x    Accelerated filer   ¨
Non-accelerated filer   ¨  (do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

At April 30, 2014, the registrant had 75,553,391 shares of Common Stock, $0.01 par value per share, outstanding.

 

 

 


Table of Contents

INDEX

 

EXPLANATORY NOTE

     2   

SIGNATURES

     3   

EXHIBIT INDEX

  

EX-10.5

  

EX-31.1

  

EX-31.2

  

 

1


Table of Contents

EXPLANATORY NOTE

This Form 10-Q/A constitutes Amendment No. 1 to the Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2014, originally filed with the Securities and Exchange Commission (the “SEC”) on May 9, 2014 (the “Original Filing”). We are filing this Amendment No. 1 to our Quarterly Report on Form 10-Q solely to file the Fifth Amendment to Lease, dated March 27, 2014, by and between the Company and ARE-MA Region No. 28, LLC (the “Lease Amendment”) as Exhibit 10.5, which was inadvertently omitted from the Original Filing. The material terms of the Lease Amendment were previously disclosed in our Current Report on Form 8-K filed with the SEC on April 2, 2014. This Amendment No. 1 does not change any other portion of the Original Filing. This Amendment No. 1 speaks as of the original filing date of the Original Filing and does not reflect events occurring after the filing date of the Original Filing, or modify or update the disclosures therein in any way other than as required to reflect the amendment described above.

 

2


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    ALNYLAM PHARMACEUTICALS, INC.
Date: January 9, 2015    

/s/ John M. Maraganore

   

John M. Maraganore, Ph.D.

Chief Executive Officer

(Principal Executive Officer)

Date: January 9, 2015    

/s/ Michael P. Mason

   

Michael P. Mason

Vice President of Finance and Treasurer

(Principal Financial and Accounting Officer)

 

3


Table of Contents

EXHIBIT INDEX

 

Exhibit

Number

  

Description

10.5    Fifth Amendment to Lease, dated March 27, 2014, by and between the Registrant and ARE-MA Region No. 28, LLC.
31.1    Certification of principal executive officer pursuant to Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.
31.2    Certification of principal financial officer pursuant to Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.